Evidence map›Paper›PMID 33106788›Full record

ArticleKidney medicine

COVID-19 in Patients Undergoing Hemodialysis: Prevalence and Asymptomatic Screening During a Period of High Community Prevalence in a Large Paris Center.

Caroline Creput, Christine Fumeron, Daniel Toledano, Mirela Diaconita, Hassan Izzedine

Abstract read
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Cognitive impairment in a patient with COVID-19 on hemodialysis: Too dangerous to neglect!Hemodialysis international. International Symposium on Home Hemodialysis · 2021
    Article
  18. Article
  19. Review
  20. COVID-19 Vaccines in Patients with Maintenance Hemodialysis.Journal of personalized medicine · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Caroline CreputNephrology and Hemodialysis Unit, Diaverum, Paris, France.
Christine FumeronNephrology and Hemodialysis Unit, Diaverum, Paris, France.
Daniel ToledanoNephrology and Hemodialysis Unit, Diaverum, Paris, France.
Mirela DiaconitaNephrology and Hemodialysis Unit, Diaverum, Paris, France.
Hassan IzzedineDepartment of Nephrology, Peupliers Private Hospital, Ramsay Générale de Santé, Paris, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

RATIONALE &

objectiveDue to extensive comorbid conditions, coronavirus disease 2019 (COVID-19) has a poor prognosis in people receiving maintenance hemodialysis. In this article, we describe our experience with 200 maintenance hemodialysis patients in a hemodialysis center that used universal reverse transcriptase-polymerase chain reaction testing, including 38 COVID-19-positive patients. STUDY

designDescriptive observational cohort, including the time line of patient diagnoses along with contextual events including precautions, testing, screening algorithms, clinical diagnostics and therapy, and the clinical course of COVID-19-infected patients and their final outcomes. SETTING &

participants200 patients within a single hemodialysis center with 2 dialysis clinics in Paris.

resultsAmong 200 maintenance hemodialysis patients, 38 (19%) had COVID-19 diagnosed; of these, 15 (39.5%) were admitted to the hospital, including 4 who required intensive care unit (ICU) care. There were 8 (21%) deaths. The most common symptom was fever, followed by dry cough, fatigue, and dyspnea. All COVID-19-infected patients had lymphopenia and an increase in C-reactive protein levels. Median time from the onset of respiratory symptoms to ICU admission was 1 to 2 days. Durations of non-ICU hospitalizations and ICU stays were 7 and 13 days, respectively. LIMITATIONS: Retrospective study, single hemodialysis center.

conclusionsDialysis patients are a highly susceptible population and hemodialysis centers are a high-risk area in a COVID-19 epidemic. "Unexplained" lymphopenia and/or an increase in C-reactive protein level should lead physicians to the diagnosis of COVID-19 and should, when possible, be followed by diagnostic testing with universal reverse transcriptase-polymerase chain reaction, as well as the reinforcement of contamination barrier measures.

Indexed as

coronavirus disease 2019COVID-19end-stage kidney diseasehemodialysismortality

Identifiers

PMID33106788
PMCPMC7577867

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.